-
Argoff CE, Katz N, Backonja M, 2004: Treatment of postherpetic neuralgia:a review of therapeutic options[J]. J Pain Symptom Manage, 28, 396-411. doi: 10.1016/j.jpainsymman.2004.01.014
-
Arvin AM (2013) Varicella-zoster virus. Fileds virology, 6th edn. Wolters Kluwer Health, Philadelphia
-
Asano Y, Itakura N, Hiroishi Y, Hirose S, Ozaki T, Kuno K, Nagai T, Yazaki T, Yamanishi K, Takahashi M, 1985: Viral replication and immunologic responses in children naturally infected with varicella-zoster virus and in varicella vaccine recipients[J]. J Infect Dis, 152, 863-868. doi: 10.1093/infdis/152.5.863
-
Asano Y, Suga S, Yoshikawa T, Kobayashi I, Yazaki T, Shibata M, Tsuzuki K, Ito S, 1994: Experience and reason:twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine[J]. Pediatrics, 94, 524-526.
-
Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barbera J, Van den Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC, Group ZOES, 2016: Efficacy of the Herpes Zoster subunit vaccine in adults 70 years of age or older[J]. N Engl J Med, 375, 1019-1032. doi: 10.1056/NEJMoa1603800
-
Deng X, Xu W, Yan R, Chen H, Shen W, Zhang M, Wu T, Xu B, He H, Ma Y, 2016: Immunogenicity and safety of different schedules of 2-dose varicella vaccination in China[J]. Hum Vaccin Immunother, 12, 3113-3117. doi: 10.1080/21645515.2016.1212795
-
Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Mansfield K, Minassian C, Langan SM, 2016: Quantification of risk factors for postherpetic neuralgia in herpes zoster patients:a cohort study[J]. Neurology, 87, 94-102. doi: 10.1212/WNL.0000000000002808
-
Galea SA, Sweet A, Beninger P, Steinberg SP, Larussa PS, Gershon AA, Sharrar RG, 2008: The safety profile of varicella vaccine:a 10-year review[J]. J Infect Dis, 197, S165-169.
-
Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, Grose C, Hambleton S, Kennedy PG, Oxman MN, Seward JF, Yamanishi K, 2015: Varicella zoster virus infection[J]. Nat Rev Dis Primers, 1, 15016-. doi: 10.1038/nrdp.2015.16
-
Jeon YH, 2015: Herpes zoster and postherpetic neuralgia:practical consideration for prevention and treatment[J]. Korean J Pain, 28, 177-184. doi: 10.3344/kjp.2015.28.3.177
-
Jiang HF, Wang W, Jiang X, Zeng WB, Shen ZZ, Song YG, Yang H, Liu XJ, Dong X, Zhou J, Sun JY, Yu FL, Guo L, Cheng T, Rayner S, Zhao F, Zhu H, Luo MH, 2017: ORF7 of varicella-zoster virus is required for viral cytoplasmic envelopment in differentiated neuronal cells[J]. J Virol, 91, e00127-.
-
Johnson BH, Palmer L, Gatwood J, Lenhart G, Kawai K, Acosta CJ, 2015a: Annual incidence rates of herpes zoster among an immunocompetent population in the United States[J]. BMC Infect Dis, 15, 502-. doi: 10.1186/s12879-015-1262-8
-
Johnson RW, Alvarez-Pasquin MJ, Bijl M, Franco E, Gaillat J, Clara JG, Labetoulle M, Michel JP, Naldi L, Sanmarti LS, Weinke T, 2015b: Herpes zoster epidemiology, management, and disease and economic burden in Europe:a multidisciplinary perspective[J]. Ther Adv Vaccines, 3, 109-120. doi: 10.1177/2051013615599151
-
Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barbera J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC, Group ZOES, 2015: Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults[J]. N Engl J Med, 372, 2087-2096. doi: 10.1056/NEJMoa1501184
-
Lo L, Anderson DJ, 2011: A Cre-dependent, anterograde transsynaptic viral tracer for mapping output pathways of genetically marked neurons[J]. Neuron, 72, 938-950. doi: 10.1016/j.neuron.2011.12.002
-
Miranda-Saksena M, Boadle RA, Diefenbach RJ, Cunningham AL, 2015: Dual role of herpes simplex virus 1 pUS9 in virus anterograde axonal transport and final assembly in growth cones in distal axons[J]. J Virol, 90, 2653-2663.
-
Oxman, Levin, Johnson, Schmader, Straus, Gelb, Arbeit, Simberkoff, Gershon, Davis, Weinberg, Boardman, Williams, Zhang, Peduzzi, Beisel, Morrison, Guatelli, Brooks, Kauffman, Pachucki, Neuzil, Betts, Wright, Griffin, Brunell, Soto, Marques, Keay, Goodman, Cotton, Gnann, Loutit, Holodniy, Keitel, Crawford, Yeh, Lobo, Toney, Greenberg, Keller, Harbecke, Hayward, Irwin, Kyriakides, Chan, Chan, Wang, Annunziato, Silber, Shingles Prevention Study Group, 2005: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults[J]. N Engl J Med, 352, 2271-2284. doi: 10.1056/NEJMoa051016
-
Pan X, Shu M, Ma R, Fang T, Dong H, Sun Y, Xu G, 2018: Varicella breakthrough infection and effectiveness of 2-dose varicella vaccine in China[J]. Vaccine, 36, 5665-5670. doi: 10.1016/j.vaccine.2018.05.025
-
Pastuszak AL, Levy M, Schick B, Zuber C, Feldkamp M, Gladstone J, Bar-Levy F, Jackson E, Donnenfeld A, Meschino W, 1994: Outcome after maternal varicella infection in the first 20 weeks of pregnancy[J]. N Engl J Med, 330, 901-905. doi: 10.1056/NEJM199403313301305
-
Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J, 2012: Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years[J]. Clin Infect Dis, 54, 922-928. doi: 10.1093/cid/cir970
-
Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P, 2008: Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life[J]. Pediatr Infect Dis J, 27, 724-730. doi: 10.1097/INF.0b013e318170bb22
-
Selariu A, Cheng T, Tang Q, Silver B, Yang L, Liu C, Ye X, Markus A, Goldstein RS, Cruz-Cosme RS, Lin Y, Wen L, Qian H, Han J, Dulal K, Huang Y, Li Y, Xia N, Zhu H, 2012: ORF7 of varicella-zoster virus is a neurotropic factor[J]. J Virol, 86, 8614-8624. doi: 10.1128/JVI.00128-12
-
Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, 1974: Live vaccine used to prevent the spread of varicella in children in hospital[J]. Lancet, 2, 1288-1290.
-
Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rothenberger CA, Fitzgerald AJ, Connor KA, McLean AA, Hilleman MR, Buynak EB, 1984: Live attenuated varicella virus vaccine. Efficacy trial in healthy children[J]. N Engl J Med, 310, 1409-1415. doi: 10.1056/NEJM198405313102201
-
Weinmann S, Chun C, Schmid DS, Roberts M, Vandermeer M, Riedlinger K, Bialek SR, Marin M, 2013: Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009[J]. J Infect Dis, 208, 1859-1868. doi: 10.1093/infdis/jit405
-
Whitley RJ, Volpi A, McKendrick M, Wijck A, Oaklander AL, 2010: Management of herpes zoster and post-herpetic neuralgia now and in the future[J]. J Clin Virol, 48, S20-28.
-
Woodward M, Marko A, Galea S, Eagel B, Straus W (2019) Varicella virus vaccine live: a 22-year review of postmarketing safety data. Open forum infectious diseases. Oxford University Press, Oxford
-
Wu QS, Wang X, Liu JY, Chen YF, Zhou Q, Wang Y, Sha JD, Xuan ZL, Zhang LW, Yan L, Hu Y, 2019: Varicella outbreak trends in school settings during the voluntary single-dose vaccine era from 2006 to 2017 in Shanghai, China[J]. Int J Infect Dis, 89, 72-78. doi: 10.1016/j.ijid.2019.09.009
-
Yoshikawa T, Ando Y, Nakagawa T, Gomi Y, 2016: Safety profile of the varicella vaccine (Oka vaccine strain) based on reported cases from 2005 to 2015 in Japan[J]. Vaccine, 34, 4943-4947. doi: 10.1016/j.vaccine.2016.08.044
-
Zeng WB, Jiang HF, Gang YD, Song YG, Shen ZZ, Yang H, Dong X, Tian YL, Ni RJ, Liu Y, Tang N, Li X, Jiang X, Gao D, Androulakis M, He XB, Xia HM, Ming YZ, Lu Y, Zhou JN, Zhang C, Xia XS, Shu Y, Zeng SQ, Xu F, Zhao F, Luo MH, 2017: Anterograde monosynaptic transneuronal tracers derived from herpes simplex virus 1 strain H129[J]. Mol Neurodegener, 12, 38-. doi: 10.1186/s13024-017-0179-7